Telaprevir
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
In combination with peg-interferon and ribavirin, telaprevir indicated for the treatment of HCV (genotype1) patients with compensated liver disease, including cirrhosis, who are treatment-naïve OR who have been previously treated with interferon-based regimen, but had no response, partial response, or relapsed (no longer available in U.S.)
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
In combination with peg-interferon and ribavirin, telaprevir indicated for the treatment of HCV (genotype1) patients with compensated liver disease, including cirrhosis, who are treatment-naïve OR who have been previously treated with interferon-based regimen, but had no response, partial response, or relapsed (no longer available in U.S.)
There's more to see -- the rest of this topic is available only to subscribers.